

Hindustan Unilever Limited Unilever House B D Sawant Marg Chakala, Andheri East Mumbai 400 099

Tel: +91 (22) 5043 3000 Web: www.hul.co.in CIN: L15140MH1933PLC002030

26th February, 2020

To,

Listing – Compliance Department National Stock Exchange of India Limited Exchange Plaza, C-1, Block G, Bandra-Kurla Complex, Bandra (East) Mumbai 400 051

This is with reference to your observation letter bearing reference no. NSE/LIST/19458 dated 15th February, 2019 regarding the Scheme of Amalgamation by way of merger by absorption among GlaxoSmithKline Consumer Healthcare Limited ("**Transferor Company**") and Hindustan Unilever Limited (the "**Company**") and their respective Shareholders and Creditors (the "**Scheme**").

We further refer to our disclosure dated November 06, 2019 wherein we had informed you that the Hon'ble National Company Law Tribunal, Mumbai Bench ("**Mumbai NCLT**"), had vide it's Order dated 24th September, 2019, sanctioned the aforesaid Scheme, and that such Order was subject to sanction of Scheme by the National Company Law Tribunal, Chandigarh Bench ("**Chandigarh NCLT**").

In this regard, we wish to inform you that the Scheme has now received the sanction of the Chandigarh NCLT. The effective date of the Scheme will be communicated to you upon being finalized by the Transferor Company and the Company, in accordance with the procedure specified under the Scheme approved by the Mumbai NCLT and Chandigarh NCLT.

alleve

For Hindustan Unilever Limited

Dev Baipai

Executive Director, Legal and Corporate Affairs

and Company Secretary DIN: 00050516 / FCS: 3354

Enclosed: A/a